For many women experiencing both menopausal symptoms and obesity, the benefits of addressing both conditions may outweigh potential risks, particularly when appropriate monitoring is in place
GLP-1s account for 23% of first line diabetes therapy in 2025 up from 3% in 2021 Since 2019, the American Diabetes Association (ADA) has revised its Standards of Care each year to expand the role of GLP-1 receptor agonists and SGLT2 inhibitors as first-line treatments for T2D 2
Those two volumes cover every format on the market and both are easy to draw accurately into a 3 mL mixing syringe
In addition to this, Canada will be the first country to see the patent on semaglutide expire, which is why Health Canada has the opportunity to authorize generic semaglutide for sale
Sources: MHRA (June 2026 licensing decision)
The ring (NuvaRing, Annovera)